Target intelligence / Profile preview

Nanog homeobox pseudogene 7 (NANOGP7)

Target
NANOGP7
Molecular classification
Other (processed pseudogene)[6]
01

Overview

Nanog homeobox pseudogene 7 (NANOGP7), also annotated as NANOGP3 in some databases, is a processed pseudogene located in the human genome within the family of NANOG homeobox pseudogenes[6]. NANOGP7 does not encode a functional protein; it lacks introns and results from retrotransposition-driven duplication of functional NANOG. In contrast, the canonical NANOG gene is an important transcription factor regulating pluripotency and self-renewal in embryonic stem cells. Unlike NANOG or the paralog NANOGP8 (which may be transcribed and expressed in some cancer contexts), NANOGP7 possesses no biological function and is not a receptor, enzyme, transporter, or established therapeutic target[6]. Naming inconsistencies (NANOGP7 versus NANOGP3) and functional confusion between the pseudogenes and the active gene are frequent in the literature[3][6]. Important note: Only the canonical NANOG is a functional protein and therapeutic target; NANOGP7, as a processed pseudogene, is nonfunctional and should not be considered a drug target, biomarker, or disease gene. Naming ambiguities are common, so refer meticulously to the canonical gene and not its pseudogenes when extracting structured data for therapeutic applications[3][6].

Other names
NANOGP3 (alternative name in some databases[6])Nanog pseudogene 3Nanog homeobox pseudogene 7
02

Mechanism of action

null. No mechanism of action is applicable.

03

Biological functions

null. As a processed pseudogene, NANOGP7 does not encode a functional protein and has no independent biological function[6].
04

Disease associations

null. There is no direct evidence that NANOGP7 itself is implicated in disease or therapeutically actionable pathways; only functional NANOG and sometimes closely related paralogs (especially NANOGP8) are studied in cancer and stem cell biology[3].
05

Safety considerations

null. There are no notable safety concerns or therapeutic challenges directly associated with NANOGP7, but confusion between functional NANOG and its pseudogenes may create research or diagnostic ambiguities[3].
06

Interacting drugs

null. No drugs are reported to interact with NANOGP7; there are no known inhibitors, agonists, or other clinical agents that modulate its function, as it is not functional[6].
07

Biomarkers

null. NANOGP7 is not used as a biomarker for patient selection or efficacy monitoring.

Beyond the preview

Go deeper on Nanog homeobox pseudogene 7 (NANOGP7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanog homeobox pseudogene 7 (NANOGP7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call